−755KRW
−27.72 BKRW
131.65 MKRW
25.77 M
About EUTILEX
Sector
Headquarters
Seoul
Employees (FY)
89
Website
Founded
2015
ISIN
KR7263050007
FIGI
BBG00MKJH1K4
Eutilex Co., Ltd. develops anti-tumor T cell therapy and antibody therapeutics based on proprietary immunotherapy technology. It offers T Cell Therapy, Antibody, CAR-T Cell Therapy. The company was founded by Kwon Byoung S on February 27, 2015 and is headquartered in Seoul, South Korea.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 263050 is 2220.00 KRW — it has increased by 2.54% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on KRX exchange EUTILEX stocks are traded under the ticker 263050.
Yes, you can track EUTILEX financials in yearly and quarterly reports right on TradingView.
Like other stocks, 263050 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade EUTILEX stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 89.00 employees. See our rating of the largest employees — is EUTILEX on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. EUTILEX EBITDA is −25.96 B KRW, and current EBITDA margin is −19.72 K%. See more stats in EUTILEX financial statements.